MedTrace Logo

Dextenza With ILUX for Treatment of MGD

NCT04658927 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-07-27

No results posted yet for this study

Summary

To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing iLUX MGD Treatment System.

Conditions

  • Meibomian Gland Dysfunction
  • Evaporative Dry Eye

Interventions

DRUG

Dexamethasone, 0.4mg

iLUX + dextenza

DRUG

Prednisone acetate

Prednisolone acetate 1% and iLux

OTHER

Control

iLUX alone.

Sponsors & Collaborators

  • Warrenville Eyecare

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-04
Primary Completion
2021-01-11
Completion
2021-05-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04658927 on ClinicalTrials.gov